Stockscreener 앱 받기
17.47
0.23%
0.04
시간 외 거래:
17.47
전일 마감가:
$17.43
열려 있는:
$17.26
하루 거래량:
412.11K
Relative Volume:
0.53
시가총액:
$6.24B
수익:
$5.21B
순이익/손실:
$-211.00M
주가수익비율:
-28.27
EPS:
-0.6179
순현금흐름:
$861.30K
1주 성능:
+5.94%
1개월 성능:
+2.46%
6개월 성능:
+10.71%
1년 성능:
+10.71%
1일 변동 폭
$17.11
$17.50
1주일 범위
$16.30
$17.50
52주 변동 폭
$14.44
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, RMD, ALC, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.47 | 6.24B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
452.29 | 159.78B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
198.91 | 54.18B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
252.86 | 35.56B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
70.17 | 33.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.09 | 29.91B | 29.14B | 1.07B | 1.05B | 1.1956 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-07 | 개시 | Barclays | Overweight |
| 2026-09-09 | 개시 | Leerink Partners | Outperform |
| 2026-07-28 | 개시 | UBS | Buy |
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Neutral |
| 2025-05-02 | 재확인 | H.C. Wainwright | Buy |
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
MarketBeat cites USD 19.46 target for Bausch + Lomb stock - ad-hoc-news.de
Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up - Benzinga
Bausch + Lomb Corporation (BLCO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bausch + Lomb Corp. (S2L.SG) Q2 FY2026 earnings call transcript - Yahoo Finance
Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation - Glance by Eyes On Eyecare
Bausch + Lomb Corporation Announces Cessation of Brent Saunders as Director, Effective October 12, 2026 - marketscreener.com
Bausch + Lomb Corporation (BLCO) Stock Forecasts - Yahoo Finance
Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief - Reuters
Thomas J. Appio Named Interim CEO of Bausch + Lomb as Brent Saunders Departs - VisionMonday.com
What Could Bausch Health (TSX:BHC) Reveal in Its Next Results? - Kalkine Media
Bausch + Lomb names Appio interim CEO as Saunders departs - StreetInsider
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance - Yahoo Finance
Bausch Health's CEO now also leads Bausch + Lomb as interim CEO. - Stock Titan
Bausch + Lomb Corporation and Bausch Health Companies Inc. Announce CEO Changes - www.marketscreener.com
Why Is Bausch + Lomb Stock Falling Monday?Bausch Health Companies (NYSE:BHC), Bausch & Lomb (NYSE:BLCO - Benzinga
Barclays Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24 - Moomoo
RBC Capital Remains a Buy on Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Bausch + Lomb's Dry Eye Disease Prescription Momentum Builds, Forex Turns as Modest Headwind in Q3, RBC Says - marketscreener.com
Barclays Reaffirms Their Buy Rating on Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Bausch & Lomb Initiated at Overweight by Barclays - Moomoo
Bausch + Lomb stock gets BL1243 update after FDA meeting - AD HOC NEWS
Why Is SeeLyra Approval Important For Bausch + Lomb (TSX:BLCO)? - Kalkine Media
Bausch + Lomb to Advance Eye Disease Treatment Following FDA Meeting - marketscreener.com
A possible medicine to take by mouth for macular degeneration is planned for 2027 testing - Stock Titan
Bausch + Lomb Sets Date for Third-Quarter 2026 Earnings Release and Investor Call - The Globe and Mail
Bausch + Lomb Corporation (TSX:BLCO): Can Vision Care Grow? - Kalkine Media
Bausch + Lomb Corporation - Baystreet.ca
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Bausch + Lomb will give a business update in a live webcast at 8 a.m. Oct. 28 - Stock Titan
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 - Business Wire
Bausch + Lomb : Review Article in Expert Review of Ophthalmology Provides a Blueprint for Patient-Centric Approaches to Dry Eye Management - marketscreener.com
Bausch + Lomb (BLCO) Stock Price, News & Analysis - MarketBeat
Bausch + Lomb (BLCO) Earnings Date and Reports 2026 - MarketBeat
Top Bausch + Lomb (BLCO) Competitors 2026 - MarketBeat
Bausch + Lomb Corporation (BLCO.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bausch + Lomb (TSX:BLCO): What Does SeeLyra Approval Mean? - Kalkine Media
Bausch + Lomb stock reports 9.1 percent revenue growth - AD HOC NEWS
Veterinary Ophthalmology Equipment Market by Product, Animal Type, Application, End User, Region Report Forecasts Market to Reach USD 0.83 Billion by 2031, Growing at a 7.7% CAGR - GlobeNewswire Inc.
Bausch Health Companies Inc. (BHC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bausch + Lomb Corporation (BLCO) Stock Analysis: Potential 12.99% Upside Beckons Investors in the Healthcare Sector - DirectorsTalk Interviews
Bausch + Lomb Q2 2026 Earnings: EPS Edges Past Estimates as Stock Slips SlightlyEarnings Forecast Report - careplusvn.com
Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026 - Yahoo Finance
Bausch + Lomb's SeeLyra femtosecond laser earns European CE mark - Ophthalmology Times
Bausch + Lomb receives CE Mark for SeeLyra laser - grafa.com
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser - investing.com
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser By Investing.com - Investing.com India
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser By Investing.com - Investing.com UK
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - Eagle-Tribune
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bausch Lomb Corp 주식 (BLCO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Munsch Frederick | Former Officer |
Aug 10 '26 |
Proposed Sale |
16.78 |
52,900 |
887,885 |
0 |
| Munsch Frederick | SVP, Controller and CAO |
Aug 10 '26 |
Sale |
16.78 |
52,900 |
887,662 |
45,831 |
| VON ESCHENBACH ANDREW C. | Former Director |
Aug 07 '26 |
Proposed Sale |
16.58 |
6,059 |
100,430 |
0 |
| VON ESCHENBACH ANDREW C. | Director |
Aug 07 '26 |
Sale |
16.58 |
6,059 |
100,458 |
63,733 |
| VON ESCHENBACH ANDREW C. | Director |
Aug 06 '26 |
Sale |
16.50 |
12,500 |
206,250 |
69,792 |
| VON ESCHENBACH ANDREW C. | Former Director |
Aug 06 '26 |
Proposed Sale |
16.50 |
12,500 |
206,193 |
0 |
| SAUNDERS BRENT L | CEO and Chairman of the Board |
Mar 06 '26 |
Buy |
17.14 |
14,700 |
251,958 |
966,575 |
| Bailey A Robert D | EVP & Chief Legal Officer |
Mar 06 '26 |
Buy |
17.15 |
14,600 |
250,332 |
231,890 |
| Eldessouky Sam | EVP and CFO |
Mar 06 '26 |
Buy |
17.13 |
4,000 |
68,520 |
403,130 |
| Ross Thomas W. Sr. | Director |
Mar 03 '26 |
Buy |
17.68 |
4,500 |
79,556 |
64,891 |
0.21%
0.27%
자본화:
|
볼륨(24시간):